Daniel Albertson, MD

Subspecialties: Genitourinary, gynecologic, breast, sarcoma, FISH, and autopsy pathology
Professor (Clinical), University of Utah School of Medicine

Specialties

• FISH
• Breast pathology
• Sarcoma pathology
• Genitourinary pathology
• Gynecologic pathology

Education

• Medical Degree—University of Nebraska
• Residency—Anatomic and Clinical Pathology, Creighton University
• Fellowship—Surgical Pathology, University of Utah

Certification/Affiliations

• United States and Canadian Academy of Pathology (Anatomic and Clinical), Diplomate
• College of American Pathologists
• National Board of Medical Examiners, Certified

Research Interests

• Oncologic genitourinary and gynecologic pathology
• Solid tumor FISH pathology
• Applications of digital pathology

Awards

• Hal Lankford Pathology Resident Award, University of Nebraska, 2011
• Outstanding Teaching Award in Anatomic Pathology, University of Utah, 2017
• The Joe Holden Award for Clinical Excellence in Anatomic Pathology, 2018

Recent Publications

• Luo MX, Lyle A, Bennett P,  et al. Artificial intelligence chatbot vs pathology faculty and residents: real-world clinical questions from a genitourinary treatment planning conference. Am J Clin Pathol. 2024. Published online Jun 2024.
• Ferrero A, Ghelichkhan E, Manoochehri H, et al. HistoEM: a pathologist-guided and explainable workflow using histogram embedding for gland classification. Mod Pathol. 2024;37(4):100447.
• Mahlow J, Barry M, Albertson DJ, et al. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway. Hum Pathol. 1013;144:28-33.
• Wilcock D, Sirohi D, Albertson D, et al. Clinicopathologic features of breast carcinoma with 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 (human epidermal growth factor receptor 2 chromosome 17 centromere ratio 2.0 and average human epidermal growth factor receptor 2 copy number ≥6.0) breast cancers. Arch Pathol Lab Med. 2023. Published online Nov 2023.
• Wilcock DM, Moore KH, Rowe L, et al. Quantitative imaging analysis fluorescence in situ hybridization validation for clinical HER2 testing in breast cancer. Arch Pathol Lab Med. 2023;147(12):1402-1412.
• Light N, Layeghifard M, Attery A, et al. Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis. Nat Commun. 2023;14(1):77.
• Wilcock DM, McMurtry V, Coleman JF, et al. Histopathological correlation of chromosome 12 polysomy by fluorescence in situ hybridization in adipocytic neoplasms. Int J Surg Pathol. 2022;30(7):734-742.
• Sirohi D, Chipman J, Barry M, et al. Histologic growth patterns in clear cell renal cell carcinoma stratify patients into survival risk groups. Clin Genitourin Cancer. 2022;20(3):e233-e243.
• Tward J, Lenz L, Flake DD II, et al. The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation [published correction appears in Int J Radiat Oncol Biol Phys. 2023;115(2):543]. Int J Radiat Oncol Biol Phys. 2022;113(1):66-76.
• Ward M, Albertson D, Furtado LV, et al. PD-L1 tumor cell expression in upper tract urothelial carcinomas is associated with higher pathologic stage. Appl Immunohistochem Mol Morphol. 2022;30(1):56-61.
• Stenehjem DD, Hahn AW, Gill DM,  et al. Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS One. 2019;14(1):e0210415.
• Gupta S, Albertson DJ, Parnell TJ, et al. Histone deacetylase inhibition has targeted clinical benefit in ARID1A-mutated advanced urothelial carcinoma. Mol Cancer Ther. 2019;18(1):185-195.